---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001909"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:38:54.031925+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences expects 2025 revenue >$340M, above guidance; core test volumes up 37% YoY

## Summary
- 2025 total revenue >$340M, above guided range of $327-335M.
- Q4 core test reports (DecisionDx-Melanoma, TissueCypher) +42% YoY.
- DecisionDx-Melanoma Q4: 10,022 reports; TissueCypher Q4: 11,803 reports.
- Year-end cash + marketable securities ~$300M.
- AdvanceAD-Tx launched Nov 2025; >50% of initial clinicians ordered in first 5 weeks.

## SEC filing metadata
- accession: 0001628280-26-001909
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000162828026001909/0001628280-26-001909-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000162828026001909/cstl-20260111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001909
- JSON: https://secwatch.observer/filing/0001628280-26-001909.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001909.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.